Correcting endometrial “defects” can gain further momentum by the presence of cancer-driver mutations such as KRAS mutations in the endometrium of women with endometriosis and the recent introduction of therapeutics aiming to rectify the effect of these mutations for cancer treatment. The gene discussed is KRAS; the disease is endometriosis.